Good Quality 66.7% 5-year Overall Survival in Terminal Lung Cancer Patients Treated With Mifepristone

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational analysis found 66.7% survival in terminal lung cancer patients treated with mifepristone, suggesting oncologists explore SPRMs further.

66.7% survival rate observed in terminal lung cancer patients treated with mifepristone, indicating a promising outcome.
Key evidence from five-year overall survival rate demonstrates effectiveness in this cohort of patients.
Observational analysis highlighting the potential for mifepristone in future clinical settings for lung cancer treatment.
Supports further investigation into selective progesterone receptor modulators in oncology for larger patient groups.

Check et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis found 66.7% survival in terminal lung cancer patients treated with mifepristone, suggesting oncologists explore SPRMs further.